{"id":"canfosfamide","rwe":[],"tags":[{"label":"canfosfamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["canfosfamide hydrochloride","TLK286","TER286","canfosfamide","canfosfamide HCl"],"offLabel":[],"synonyms":["canfosfamide hydrochloride","TLK286","TER286","canfosfamide","canfosfamide HCl"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"canfosfamide","explanation":"Imagine canfosfamide as a molecular 'glue' that attaches to DNA, making it impossible for cancer cells to make copies of themselves. This prevents the cancer cells from growing and dividing, eventually leading to their death. By targeting the DNA of cancer cells, canfosfamide can help slow or stop the growth of tumors.","oneSentence":"Canfosfamide works by cross-linking DNA, preventing cancer cells from replicating and ultimately leading to cell death.","technicalDetail":"Canfosfamide exerts its cytotoxic effects through the formation of DNA cross-links, which interfere with DNA replication and transcription, ultimately leading to cell death through apoptosis or necrosis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3062","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CANFOSFAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CANFOSFAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:10:17.530340","biosimilars":[],"competitors":[],"genericName":"canfosfamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00350948","phase":"PHASE3","title":"Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Telik","startDate":"2006-05","conditions":["Ovarian Neoplasms"],"enrollment":244,"completionDate":"2008-12"},{"nctId":"NCT00036920","phase":"PHASE2","title":"TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-01","conditions":["Lung Cancer"],"enrollment":0,"completionDate":"2009-12"},{"nctId":"NCT00022347","phase":"PHASE2","title":"TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-05","conditions":["Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer"],"enrollment":0,"completionDate":"2009-12"},{"nctId":"NCT01148108","phase":"PHASE2","title":"Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma","status":"COMPLETED","sponsor":"Telik","startDate":"2010-06","conditions":["Mantle Cell Lymphoma","B Cell Lymphoma","Multiple Myeloma"],"enrollment":14,"completionDate":"2012-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1RS284BFUI","CHEBI":"CHEBI:135883","INN_ID":"8455","UMLSCUI":"C2827096","ChEMBL_ID":"CHEMBL2111086","KEGG_DRUG":"D03351","DRUGBANK_ID":"DB04972","PUBCHEM_CID":"5312109","SECONDARY_CAS_RN":"439943-59-6","MESH_SUPPLEMENTAL_RECORD_UI":"C107479"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.28 hours","clearance":"28.5 mL/min/kg","volumeOfDistribution":"0.46 L/kg"},"publicationCount":14,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CANFOSFAMIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Canfosfamide is a small molecule chemotherapeutic agent in the canfosfamide drug class. Its target is unknown, and it has not been FDA approved for any indications. As a chemotherapeutic agent, canfosfamide works by interfering with DNA replication and cell division, ultimately leading to cell death. The commercial status of canfosfamide is unclear, and it may be patented or available as a generic product. Key safety considerations include its short half-life of 0.28 hours.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}